Related Experiment Video

Updated: Jul 6, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Randomized trial of bevacizumab in advanced renal cell carcinoma

Ronald M Bukowski

    Current Oncology Reports
    |April 2, 2008
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)
    04:11

    A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

    Published on: June 9, 2026

    Related Experiment Videos

    Last Updated: Jul 6, 2026

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)
    04:11

    A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

    Published on: June 9, 2026

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

    Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure.

    Clinical genitourinary cancer·2020

    Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

    Journal for immunotherapy of cancer·2016

    The Cost of Hope: a candid roundtable discussion.

    Journal of the National Comprehensive Cancer Network : JNCCN·2013

    Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2012

    Temsirolimus: a safety and efficacy review.

    Expert opinion on drug safety·2012

    Navigating Antibody-Drug Conjugate Sequencing in Gastric Cancer: Cross-Resistance Biology, Target Switching, and Decision-Making Frameworks for the Post-Progression Landscape.

    Current oncology reports·2026

    Artificial Intelligence for Diagnosis, Risk Stratification, and Prognosis of Neuroblastoma - A Systematic Review and Meta-Analysis.

    Current oncology reports·2026

    Tele-Oncology in the Post-Pandemic Era: Clinical Integration, Access Disparities and Medico-Legal Accountability.

    Current oncology reports·2026

    Role of Interventional Oncology in the Management of Neuroendocrine Tumors: 2026 Update.

    Current oncology reports·2026

    GLP-1 Receptor Agonists and Obesity Related Cancers: What We Know So Far.

    Current oncology reports·2026

    Head and Neck Rhabdomyosarcoma in Children: An Otolaryngological Perspective on Diagnostic and Therapeutic Approaches.

    Current oncology reports·2026

    Evolving person-focused cancer care: the multifaceted benefits of electronic PRO integration and radiation therapist-led follow-up in radiotherapy.

    Technical innovations & patient support in radiation oncology·2026

    C-X-C Motif Chemokine Receptor 4 (CXCR4)-Targeted Biologically Guided Proton Spatially Fractionated Radiotherapy for Bulky Limited-Stage Small Cell Lung Cancer.

    Precision radiation oncology·2026

    Radiotherapy for postoperative groin lymphatic fistulas: A systematic review of clinical outcomes and treatment planning.

    Clinical and translational radiation oncology·2026

    Re-evaluating the α/β ratio in 2026: A systematic review and quantitative reappraisal in the era of molecular radiobiology.

    Medical dosimetry : official journal of the American Association of Medical Dosimetrists·2026

    Clinical and Treatment Factors associated with Lymphopenia after Palliative Radiation Therapy in Cancer Patients.

    International journal of radiation oncology, biology, physics·2026

    Bayesian personalized dose constraints in selecting patients with non-small cell lung cancer for cardiac risk-adaptive treatment.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us